|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diagnosis,prevention,and management of delirium:summary of NICE guigance显示文摘 | Young J Murthy L Westby M | | 0，，： | 1 |
| 2 | Regular aerobic exercise, without weight loss, improves endothelium- depengdent vasodilation in overweight and obese adults 显示文摘 | MESTEK M L WESTBY C M VAN GUILDER G P | 2010 | Obesity (Silver Spring)2010，18，： | 1 |
| 3 | Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry显示文摘 | Westby M Smith-Burchnell C Mori J | 2007 | J Virol2007，81，： | 1 |
| 4 | CC-3052: a watersoluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production显示文摘 | Marriot JB Westby M Cookson S | 1998 | J Immunol1998，161，8： | 1 |
| 5 | Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity 显示文摘 | Dorr P Westby M Dobbs S | 2005 | Antimicrob Agents Chemother2005，49，： | 1 |
| 6 | Maraviroc (UK-427,857), a potert, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency vires type 1 activity显示文摘 | Dorr P Westby M Dobbs S | 2005 | Antimicrob Agents Chemother2005，49，11： | 1 |
| 7 | Maraviroc (UK 427, 857), a potent, orally bioavailable, and selective small molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunodeficiency virus type 1 activity显示文摘 | Dorr P Westby M Dobbs S | 2005 | Antimicrob Ag Chemother2005，49，11： | 1 |
| 8 | CC-3052:a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production显示文摘 | MARRIOTT JB WESTBY M COOKSON S | 1998 | J Immunol1998，161，8： | 1 |
| 9 | Cellbased and biochemical screening approaches for the discovery of novel HIV-1 inhibitors显示文摘 | Westby M Nakayama GR Butler SL Blair WS | | 0，，03： | 1 |
| 10 | Cell-based and biochemical screening approaches for the discovery, of novel HIV-1 inhibitors显示文摘 | Westby M Nakayama G R Butler S L | 2005 | Antiviral Res2005，67，： | 1 |
| 11 | Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy 显示文摘 | Butler S L Valdez H Westby M | 2011 | J Acquir Immune Defic Syndr2011，58，3： | 1 |
| 12 | Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-uslng virus reservoir显示文摘 | Westby M Lewis M Whitcomb J | 2006 | J Virol2006，80，10： | 1 |
| 13 | Resistance to CCR5 antagonists 显示文摘 | Westby M | 2007 | Curr Opin HIV AIDS2007，2，： | 1 |
| 14 | Diagnosis,prevention,and management of delirium : summary of NICE guidance显示文摘 | Young J Murthy L Westby M | 2010 | BMJ2010，341，： | 1 |
| 15 | Strategy shifts in leaf physiology, structure and nutrient content between species of high and low rainfall and high and low nutrient habitats 显示文摘 | Wright I J Reich P B Westby M | 2001 | Functional Ecolo- gy2001，15，4： | 1 |
| 16 | Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibi- tor of chemokine receptor CCR5 with broad-spectrum antihuman immuno-deficiency virus type 1 activity显示文摘 | Dorr P Westby M Dobbs S etal | 2005 | Antimicrob Agents Chemother2005，49，11： | 1 |
| 17 | A comparison of handsearching versus EDLINE searching to identify reports of randomized controlled trials显示文摘 | Hopewell S Clarke M Lusher A Lefebvre C Westby M | 2002 | Stat Med2002，21，11： | 1 |
| 18 | Patient and health professional views on rehabilitation practices and outcomes following total hip and knee arthroplasty for osteoarthritis: a focus group study显示文摘 | Westby M D Baekman C L | 2010 | BMC Health Serv Res2010，10，： | 1 |
| 19 | Maraviroc (UK-d27, 857 ), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti- human immunodeficiency virus type 1 activity 显示文摘 | DORR P WESTBY M DOBBS S | 2005 | Antimicrob A- gents Chemother2005，49，11： | 1 |
| 20 | Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry显示文摘 | Westby M Smith-Burchnell C Mori J | 2007 | J Virol2007，81，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员